The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer
Open accessAbstract
Colorectal cancer (CRC) is a leading cause of cancer death worldwide. It includes different subtypes that differ in their clinical and prognostic features. In the past decade, in addition to the conventional adenoma-carcinoma model, an alternative multistep mechanism of carcinogenesis, namely the “serrated pathway”, has been described. Approximately, 15 to 30% of all CRCs arise from neoplastic serrated polyps, a heterogeneous group of lesions that are histologically classified into three morphologic categories: hyperplastic polyps, sessile serrated adenomas/polyps, and the traditional serrated adenomas/polyps. Serrated polyps are characterized by genetic (BRAF or KRAS mutations) and epigenetic (CpG island methylator phenotype (CIMP)) alterations that cooperate to initiate and drive malignant transformation from normal colon mucosa to polyps, and then to CRC. The high heterogeneity of the serrated lesions renders their diagnostic and pathological interpretation difficult. Hence, novel genetic and epigenetic biomarkers are required for better classification and management of CRCs. To date, several molecular alterations have been associated with the serrated polyp-CRC sequence. In addition, the gut microbiota is emerging as a contributor to/modulator of the serrated pathway. This review summarizes the state of the art of the genetic, epigenetic and microbiota signatures associated with serrated CRCs, together with their clinical implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 4×
“HNPCC is an autosomal dominant disease due to germline mutations in some MMR genes (e.g., MSH2, MLH1, MSH6, PMS2, and PMS1), causing consequent inactivation of the DNA repair system and the accumulation of mutated microsatellites [24].”
BackgroundInfluentialMultitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 1×
“They allow distinguishing between SSA/Ps and conventional adenomas [79,80].”
BackgroundAnalysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., Neuberg, D., Huang, K., Guevara, F., Nelson, T., et al. (2017) · Science · doi:10.1126/science.aal5240 · Cited by 1,574 · cited 1×
“nucleatum has been associated with CRC progression [153,154].”
BackgroundThe Integrative Human Microbiome Project
The Integrative HMP (iHMP) Research Network Consortium, Proctor, L. M., Creasy, H. H., Fettweis, J. M., Lloyd-Price, J., Mahurkar, A., Zhou, W., Buck, G. A., Snyder, M. P., Strauss, J. F., et al. (2019) · Nature · doi:10.1038/s41586-019-1238-8 · Cited by 1,381
The role of the gut microbiome in the healthy adult status
D’Argenio, V., & Salvatore, F. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.003 · Cited by 492 · cited 1×
“Human gut microbiota, whose composition varies across gut segments and between individuals, plays a multitude of functions, such as structural and metabolic roles or homeostasis maintenance of the intestinal immune system which constitutes a natural barrier to pathogen infection [142,143].”
BackgroundSelf-citationMicrobiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510353 · Cited by 426
Ito, M., Kanno, S., Nosho, K., Sukawa, Y., Mitsuhashi, K., Kurihara, H., Igarashi, H., Takahashi, T., Tachibana, M., Takahashi, H., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29488 · Cited by 288 · cited 2×
“nucleatum was not associated with serrated precursor polyps, but was related to CIMP-H status and to large tumors, comforting its role in CRC progression [157].”
Background
Cited by
Sawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021) · Cancers · doi:10.3390/cancers13092025 · Cited by 921
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
“In the MSI pathway and the CIMP pathway, genetic alterations preferentially lead to serrated polyps, which have been described as “flat adenomas” [12,13].”
BackgroundLanauze, C. B., Sehgal, P., Hayer, K., Torres-Diz, M., Pippin, J. A., Grant, S. F. A., & Thomas-Tikhonenko, A. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0721 · Cited by 17
Metadata
- Authors
- De Palma, F., D’Argenio, V., Pol, J., Kroemer, G., Maiuri, M., & Salvatore, F.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-07-20
- Volume
- 11
- Issue
- 7
- Pages
- 1017
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2963202264
- Cited by
- 213
- References
- 14
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cancers11071017
- The paper
- De Palma, F., D’Argenio, V., Pol, J., Kroemer, G., Maiuri, M., & Salvatore, F. (2019). The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers. https://doi.org/10.3390/cancers11071017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.